Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment

Journal of Clinical Investigation

Volumn 119, Issue 4, 2009, Pages 997-1007

  Levy, Yves ^a,h   Lacabaratz, Christine ^a   Weiss, Laurence ^b   Viard, Jean Paul ^c   Goujard, Cecile ^d   Lelièvre, Jean Daniel ^a   Boué, François ^e   Molina, Jean Michel ^f   Rouzioux, Christine ^c   Avettand Fénoêl, Véronique ^c   Croughs, Thérèse ^g   Beq, Stéphanie ^g   Thiébaut, Rodolphe ^d   Chêne, Geneviève ^d   Morre, Michel ^g   Delfraissy, Jean François ^d  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSERM   (France)

^e HÔPITAL ANTOINE BÉCLÈRE   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g Cytheris   (France)

^h HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 7; VIRUS RNA; IL7 PROTEIN, HUMAN; INTERLEUKIN 7; RECOMBINANT PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NATURAL KILLER CELL; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; T LYMPHOCYTE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; ADULT; AGED; CD4 CD8 RATIO; CELL CYCLE; DRUG EFFECT; DRUG TOLERANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTOPENIA; MIDDLE AGED; PATHOLOGY; SAFETY; VIROLOGY;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CELL CYCLE; DRUG TOLERANCE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-7; LYMPHOCYTE ACTIVATION; LYMPHOPENIA; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SAFETY; T-LYMPHOCYTES;

EID: 65249105408     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI38052     Document Type: Article

References (69)

1. Hammer, S.M., et al. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337:725-733.
2. Mocroft, A., et al. 1998. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 352:1725-1730.
3. Palella, F.J., Jr., et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853-860.
4. Grabar, S., et al. 2000. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 133:401-410.
5. Moore, D.M., et al. 2006. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy. HIV Med. 7:311-316.
6. Gras, L., et al. 2007. CD4 cell counts of 800 cells/ mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J. Acquir. Immune Defic. Syndr. 45:183-192.
7. Rodriguez, B., et al. 2006. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 296:1498-1506.
8. Antiretroviral Therapy Cohort Collaboration. 2008. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 372:293-299.
9. Smit, C., et al. 2006. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 20:741-749.
10. Weber, R., et al. 2006. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch. Intern. Med. 166:1632-1641.
11. Lewden, C., et al. 2008. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J. Acquir. Immune Defic. Syndr. 48:590-598.
12. El-Sadr, W.M., et al. 2006. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355:2283-2296.
13. Baker, J.V., et al. 2008. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J. Acquir. Immune Defic. Syndr. 48:541-546.
14. Baker, J.V., et al. 2008. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 22:841-848.
15. Hazenberg, M.D., et al. 2003. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 17:1881-1888.
16. Hunt, P.W., et al. 2003. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 187:1534-1543.
17. Jameson, S.C. 2002. Maintaining the norm: T-cell homeostasis. Nat. Rev. Immunol. 2:547-556.
18. Douek, D.C., Picker, L.J., and Koup, R.A. 2003. T cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 21:265-304.
19. Fry, T.J., et al. 2001. A potential role for interleukin-7 in T-cell homeostasis. Blood. 97:2983-2990.
20. Grabstein, K.H., et al. 1993. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J. Exp. Med. 178:257-264.
21. Murray, R., Suda, T., Wrighton, N., Lee, F., and Zlotnik, A. 1989. IL-7 is a growth and maintenance factor for mature and immature thymocyte subsets. Int. Immunol. 1:526-531.
22. Puel, A., Ziegler, S.F., Buckley, R.H., and Leonard, W.J. 1998. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat. Genet. 20:394-397.
23. von Freeden-Jeffry, U., et al. 1995. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 181:1519-1526.
24. Schluns, K.S., Kieper, W.C., Jameson, S.C., and Lefrancois, L. 2000. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 1:426-432.
25. Mackall, C.L., et al. 2001. IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood. 97:1491-1497.
26. Vassena, L., Proschan, M., Fauci, A.S., and Lusso, P. 2007. Interleukin 7 reduces the levels of spontaneous apoptosis in CD4+ and CD8+ T cells from HIV-1-infected individuals. Proc. Natl. Acad. Sci. U. S. A. 104:2355-2360.
27. Lelievre, J., Berry, A., and Benoit-Vical, F. 2007. Artemisinin and chloroquine: do mode of action and mechanism of resistance involve the same protagonists? Curr. Opin. Investig. Drugs. 8:117-124.
28. Malaspina, A., et al. 2006. Appearance of immature/ transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc. Natl. Acad. Sci. U. S. A. 103:2262-2267.
29. Kimmig, S., et al. 2002. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J. Exp. Med. 195:789-794.
30. Fry, T.J., et al. 2003. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIVinfected nonhuman primates. Blood. 101:2294-2299.
31. Sportes, C., et al. 2008. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 205:1701-1714.
32. Purton, J.F., Martin, C.E., and Surh, C.D. 2008. Enhancing T cell memory: IL-7 as an adjuvant to boost memory T-cell generation. Immunol. Cell Biol. 86:385-386.
33. Nanjappa, S.G., Walent, J.H., Morre, M., and Suresh, M. 2008. Effects of IL-7 on memory CD8 T cell homeostasis are influenced by the timing of therapy in mice. J. Clin. Invest. 118:1027-1039.
34. Schmitt, N., et al. 2003. Positive regulation of CXCR4 expression and signaling by interleukin-7 in CD4+ mature thymocytes correlates with their capacity to favor human immunodeficiency X4 virus replication. J. Virol. 77:5784-5793.
35. Smithgall, M.D., Wong, J.G., Critchett, K.E., and Haffar, O.K. 1996. IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. J. Immunol. 156:2324-2330.
36. Chene, L., et al. 1999. Thymocyte-thymic epithelial cell interaction leads to high-level replication of human immunodeficiency virus exclusively in mature CD4(+) CD8(-) CD3(+) thymocytes: a critical role for tumor necrosis factor and interleukin-7. J. Virol. 73:7533-7542.
37. Lederman, M.M., and Valdez, H. 2000. Immune restoration with antiretroviral therapies: implications for clinical management. JAMA. 284:223-228.
38. Teixeira, L., et al. 2001. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 15:1749-1756.
39. Smith, C.J., et al. 2004. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J. Infect. Dis. 190:1860-1868.
40. Viard, J.P., et al. 2001. Influence of age on CD4 cell recovery in human immunodeficiency virusinfected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J. Infect. Dis. 183:1290-1294.
41. Florence, E., et al. 2003. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the Euro-SIDA study. HIV Med. 4:255-262.
42. Douek, D.C., et al. 1998. Changes in thymic function with age and during the treatment of HIV infection. Nature. 396:690-695.
43. Kaufmann, G.R., et al. 2005. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis. 41:361-372.
44. Kovacs, J.A., et al. 1995. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 332:567-575.
45. Kovacs, R.G., and Aguayo, S.M. 1993. Images in clinical medicine. Superior vena cava syndrome. N. Engl. J. Med. 329:1007.
46. Levy, Y., et al. 1999. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet. 353:1923-1929.
47. Levy, Y., et al. 2003. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS. 17:343-351.
48. Beq, S., et al. 2006. IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J. Immunol. 176:914-922.
49. Storek, J., et al. 2003. Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. Blood. 101:4209-4218.
50. Rosenberg, S.A., et al. 2006. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 29:313-319.
51. Wang, F.X., et al. 2005. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J. Clin. Invest. 115:128-137.
52. Schluns, K.S., and Lefrancois, L. 2003. Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol. 3:269-279.
53. Kaech, S.M., et al. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4:1191-1198.
54. Carini, C., McLane, M.F., Mayer, K.H., and Essex, M. 1994. Dysregulation of interleukin-7 receptor may generate loss of cytotoxic T cell response in human immunodeficiency virus type 1 infection. Eur. J. Immunol. 24:2927-2934.
55. Paiardini, M., et al. 2005. Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J. Immunol. 174:2900-2909.
56. Mastroianni, C.M., et al. 2001. Circulating levels of interleukin-7 in antiretroviral-naive and highly active antiretroviral therapy-treated HIV-infected patients. HIV Clin. Trials. 2:108-112.
57. Llano, A., et al. 2001. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J. Virol. 75:10319-10325.
58. Napolitano, L.A., et al. 2001. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat. Med. 7:73-79.
59. Sasson, S.C., et al. 2006. Increased plasma interleukin-7 level correlates with decreased CD127 and Increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection. J. Infect. Dis. 193:505-514.
60. Dunham, R.M., et al. 2008. CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection. J. Immunol. 180:5582-5592.
61. Silvestri, G., and Feinberg, M.B. 2003. Turnover of lymphocytes and conceptual paradigms in HIV infection. J. Clin. Invest. 112:821-824.
62. McCune, J.M. 2001. The dynamics of CD4+ T-cell depletion in HIV disease. Nature. 410:974-979.
63. Douek, D.C., et al. 2000. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet. 355:1875-1881.
64. Ducrey-Rundquist, O., Guyader, M., and Trono, D. 2002. Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. J. Virol. 76:9103-9111.
65. Scripture-Adams, D.D., Brooks, D.G., Korin, Y.D., and Zack, J.A. 2002. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J. Virol. 76:13077- 13082.
66. Avettand-Fenoel, V., Boufassa, F., Galimand, J., Meyer, L., and Rouzioux, C. 2008. HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. J. Clin. Virol. 42:399-404.
67. Agence nationale de recherches sur le sida et les hépatites virales. 2008. ANRS scale to grade the severity of adverse events in adults. http://www.anrs.fr/ index.php/anrs/content/download/2242/12805/ file/ANRS-GradeEI-V1-En-2008.pdf.
68. Losso, M., Abrams, D., and INSIGHT ESPRIT Study Group. 2009. Effect of interleukin-2 on clinical outcomes in patients with a CD4+ cell count of 300/mm3: primary results of the ESPRIT study. Abstract no. 90aLB presented at the 16th Conference on Retroviruses and Opportunistic Infections. February 8-11. Montreal, Quebec, Canada.
69. Levy, Y., and SILCAAT Sci Committee. 2009. Effect of interleukin-2 on clinical outcomes in patients with CD4+ cell count 50 to 299/mm3: primary results of the SILCAAT study. Abstract no. 90bLB presented at the 16th Conference on Retroviruses and Opportunistic Infections. February 8-11. Montreal, Quebec, Canada.